BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 32683991)

  • 1. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
    Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
    Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab.
    Koulouris A; Mountzios G
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):651-659. PubMed ID: 33902379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
    Cooper MR; Alrajhi AM; Durand CR
    Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
    Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
    Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
    Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
    Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.
    Yamamoto K; Ninomaru T; Okada H; Hirano K; Shimada T; Hata A
    Thorac Cancer; 2024 May; 15(15):1271-1275. PubMed ID: 38623812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
    Ragavan M; Das M
    Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
    Pavan A; Attili I; Pasello G; Guarneri V; Conte PF; Bonanno L
    J Immunother Cancer; 2019 Aug; 7(1):205. PubMed ID: 31383005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    Ma X; Wang S; Zhang Y; Wei H; Yu J
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade in small cell lung cancer.
    Tay RY; Heigener D; Reck M; Califano R
    Lung Cancer; 2019 Nov; 137():31-37. PubMed ID: 31525648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immunotherapy in small cell lung cancer.
    Calles A; Aguado G; Sandoval C; Álvarez R
    Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
    Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
    Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future therapeutic approaches for the treatment of small cell lung cancer.
    Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
    Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.